⌘K
Loading ticker…
As of 2026-08-24, Aclaris Therapeutics, Inc. (ACRS) has a 3-month relative strength percentile of 91 and a leadership percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 83. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.0%, relative volume 0.62×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ACRS is in a stage 2 uptrend, week 10. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 15.2% / 56.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ACRS is held by 14 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $2M notional. Top 3 carry $4M.
Held by 28 ETFs · $41M across latest filings · largest weight 0.65% (QQQS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| +0.17 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $30K | — |
| IBBQ | 0.04% | $29K | +0.02 pp |
| BIB | 0.03% | $20K | +0.01 pp |
| ITWO | 0.01% | $20K | — |
Showing 10 of 14 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACRS Jan avg: 8.60% median: 8.89% win: 100% σ: 6.91% n: 4 2022-04-12 → 2026-07-31 | ACRS Feb avg: -15.42% median: -19.00% win: 25% σ: 12.50% n: 4 2022-04-12 → 2026-07-31 | ACRS Mar avg: -5.83% median: -9.46% win: 50% σ: 29.36% n: 4 2022-04-12 → 2026-07-31 | ACRS Apr avg: -1.82% median: -2.42% win: 40% σ: 15.31% n: 5 2022-04-12 → 2026-07-31 | ACRS May avg: -1.30% median: 3.82% win: 60% σ: 8.96% n: 5 2022-04-12 → 2026-07-31 | ACRS Jun avg: 10.73% median: 9.15% win: 80% σ: 10.14% n: 5 2022-04-12 → 2026-07-31 | ACRS Jul avg: 6.69% median: 7.75% win: 60% σ: 10.57% n: 5 2022-04-12 → 2026-07-31 | ACRS Aug avg: -1.69% median: -4.35% win: 50% σ: 21.69% n: 4 2022-04-12 → 2026-07-31 (current) | ACRS Sep avg: -3.40% median: -2.05% win: 0% σ: 3.41% n: 4 2022-04-12 → 2026-07-31 | ACRS Oct avg: 15.47% median: 15.90% win: 50% σ: 37.18% n: 4 2022-04-12 → 2026-07-31 | ACRS Nov avg: 13.06% median: 4.90% win: 50% σ: 85.37% n: 4 2022-04-12 → 2026-07-31 | ACRS Dec avg: -2.30% median: 4.92% win: 75% σ: 25.56% n: 4 2022-04-12 → 2026-07-31 |